|
|
|
3i Initiative Weekly Updates
Welcome to the 3i Weekly Update, your source for 3i relevant news and events. Please send all items of interest to Nicole.Frank@hsc.utah.edu by the end of the day on Thursdays.
| |
|
|
4/9- 4/16- MONDAY, APRIL 5 – FRIDAY, APRIL 9, 2021 - 2nd Annual Symposium for Underserved, Rural, and Global Education
- FRIDAY, APRIL 9, 2021, 11:45 AM – 2PM - Biomedical Engineering Seminar - Dr. Linda Liau - Overcoming Immunotherapy Resistance in Glioblastoma
- FRIDAY, APRIL 9, 2021, 12 – 1PM - Microbial Pathogenesis Seminar Series - Dr. Christina Hull - How to Kill Pathogenic Spores Before They Kill You
- FRIDAY, APRIL 9, 2021, 12 – 1PM - NEXUS Dialogues on Disparities - Racial Societal Stressors and Population-Level Health Outcomes"
- MONDAY, APRIL 12, 2021, 4 – 5PM - Pharmaceutics & Pharmaceutical Chemistry Seminars - Dr. Moein Moghimi - The Complement System: Complement Propriety and Conspiracy in Nanomedicine
- TUESDAY, APRIL 13, 2021, 12 – 1PM - Research Professionals Grand Rounds - Dr. Michael Dean - How YOU Can Scare Your Investigator into Submission
- TUESDAY, APRIL 13, 2021, 12 – 1PM - Dr. Christy Porucznik - The C-HEaRT Study: Studying COVID-19 in Utah Families
- WEDNESDAY, APRIL 14, 2021, 12 – 1PM - NIH Grants 101 and the Early Career Reviewer (ECR) Program
- WEDNESDAY, APRIL 21, 2021, 2 – 3PM - Biomedical Engineering Colloquium: Dr. Susan Bock - “Broadly Protective Flu Vaccines”
| |
|
- 3i Initiative Spring 2021 Symposium - FRIDAY, ARPIL 30, 2021, 8:00 AM -5:00 PM
- Annual Symposium: Sex, Gender and Women’s Health Across the Lifespan - THURSDAY, MAY 13, 2021
- 2021 COVID-19 Symposium - FRIDAY, JUNE 4, 2021, 8:00 AM -5:00 PM
| |
|
- Differences Deep Within Cells May Explain Why Some Patients Recover from Heart Failure (Stavros Drakos, Cardiovascular Medicine; Jared Rutter, Biochemistry)
- University of Utah Health Research Plays Major Role in New CDC Guidelines (Adam Hersh, Pediatric Infectious Diseases; Andy Pavia, Pediatric Infectious Diseases)
- COVID-19 Vaccines as Effective in Real-World Settings as in Clinical Trials (Sarang Yoon, Family and Preventive Medicine; Kurt Hegmann, Occupational and Environmental Health; Matthew Thiese, Family and Preventive Medicine; Andrew Phillips; Occupational and Environmental Health)
- The Atlantic: Cone Snails Are Liars and Murderers (Eric Schmidt, Medicinal Chemistry)
- University of Utah researchers studying possible COVID-19 treatment — an old antidepressant (Adam Spivak, Infectious Diseases)
- USA Today: "Superbugs' kill more than 35K people in the US each year. Doctors may be partially to blame, study suggests (Matthew Samore, Internal Medicine, Biomedical Informatics)
- KSLTV: Trial Underway To Determine Whether COVID-19 Vaccines Prevent Spread (Emily Spivak, Infectious Diseases)
- Medical News Today: Foodborne fungus may disrupt gut healing in Crohn’s disease (Tyson Chiaro, Pathology; June Round, Pathology, Huntsman Cancer Institute)
| |
|
|
- Call for applications: 3i Training Grant - We are pleased to announce that we are accepting applications from graduate students for the Immunology, Infectious Disease and Inflammation (3i) Training Grant (3iTG). The Training Grant will provide support for one year, with the potential to renew for a second year of support. We will be appointing 2 graduate student trainees this year. Some of the features of the training program include support for mentored research, a clinical immunology rotation at ARUP (pandemic permitting), training in data analysis and publishing, grant writing and career planning, mentored preparation and submission of F award proposal or equivalent, yearly presentation of data to the immunology community and partial support for travel to scientific meetings to present research findings. See application instructions here. Applications are due April 12th, 2021
- CCTS Peer Grant Review Program - Now Accepting Research Proposals for Pre-Submission Peer Review - The Utah Center for Clinical and Translational Science (CCTS) is now accepting research proposals for pre-submission peer review. The program accepts proposals from investigators conducting research at any point along the translational science spectrum aiming to improve the health of individuals and the public. Please limit one proposal submission per investigator to the PGR. NIH review criteria will be used to score each submission. Formal reviews will be returned to the investigator by May 3, 2021. Submission Requirements Investigators are required, via email, to submit a) the completed CCTS Peer Grant Review Face Page form (see below or fillable version); b) their NIH Biographical Sketch, Specific Aims, Research Strategy, and Bibliography & References Cited as word documents; and c) any other appropriate ancillary documents as a single PDF (see Guidance Checklists) to Breanne Johnson (Breanne.Johnson@hsc.utah.edu) no later than 4:00 pm on Thursday, April 23rd, 2021.
- Hatch Scholar for T1D Research - Request for Applications - due April 30, 2021 - We are pleased to announce the sixth annual Hatch Family Scholar Award Competition for graduate students and postdoctoral fellows at the University of Utah. The purpose of this award is to honor the Hatch family by rewarding a junior research scientist that is conducting research in the field of Type 1 Diabetes. A minimum prize of $1,000 will be awarded. Prizes are subject to federal tax regulations. Applications and all supporting documents should be compiled as one PDF and submitted electronically through the University of Utah’s Competition Space interface at http://utah.infoready4.com/ by April 30, 2021 at 5pm, search “The Paul Shurtleff Hatch and Heidi Hatch Ford Scholar Award for Type 1 Diabetes Research.” See attached RFA for more details.
| |
|
- Open Postdoctoral Research Position - Tumor Immunology - The Department of Internal Medicine, Division of Gastroenterology is seeking a highly motivated Postdoctoral Fellow to study novel immunotherapy approaches for gastrointestinal cancers. Experience with mouse work, flow cytometry, and immune cell assays is preferable. Applicants must have obtained a PhD in cancer biology, immunology, or a related field within the past three years. Strong oral and written English skills are required. The successful candidate should have independent research skills and a track record of success in the laboratory.
Interested applicants please submit a CV and contact information for 3 references to ellen.beswick@hsc.utah.edu
- Open Postdoctoral Research Position - The Puri Lab at the University of Utah seeks to hire a postdoctoral research associate to work on a funded project studying the biosynthesis of natural products made by underexplored bacteria. The ideal candidate will have a Ph.D. in Biochemistry, Chemistry, Microbiology, or a related field, and experience with protein expression, purification, and enzymology. Interested applicants should contact Aaron Puri directly (a.puri@utah.edu) with a cover letter, CV, and contact information for 3 references.
- SEAL (Science Excelerator and Leadership) Program Position Open - With this change in mind, the Gregg lab at the University of Utah is transitioning to a new model of science and discovery that caters to professional scientists by launching the SEAL (Science Excelerator and Leadership) Program. We are investigating new ways to take on higher impact scientific problems and make major advances in a shorter period of time. To help with this, the lab will transition to a new name – the Precision Brain Genetics Lab. This name change reflects the focus of the science and important roles of senior investigators in the lab and their capability to obtain independent grants if they wish. Right now, we are seeking to recruit a new SEAL program scientist to the lab at the level of a career track assistant professor, staff scientist or postdoctoral fellow.
| |
|
|
3i Funding Opportunities
Current Federal and Private FOAs applicable to the 3is can be found on the U's pivot page. New FOAs announced this week:
- Limited Submission Opportunities. Contact Lynn Wong, Director of Foundation Relations with any questions. Applications are submitted through InfoReady.
- RFA-AI-21-018, Limited Interaction Targeted Epidemiology (LITE-2)—To Advance HIV Prevention (UG3/UH3, Clinical Trial Optional)
- RFA-AI-21-013, Understanding HIV Reservoir Dynamics (P01, Clinical Trial Not Allowed)
- RFA-AI-21-019, Radiation-Induced Immune Dysfunction (U01, Clinical Trial Not Allowed)
- RFA-AR-21-015, Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases—Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjogren's Syndrome (UC2, Clinical Trial Optional)
- PAR-21-109, Early-Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21, Clinical Trial Not Allowed)
- RFA-RM-21-012 - Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
- NOT-MH-21-225 - Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children
- NOT-HL-21-006 - Notice of Intent to Publish a Funding Opportunity Announcement for the ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01)
- PAR-21-213 - Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)
- NSF - Trans-Atlantic Platform Recovery, Renewal, and Resilience in a Post-Pandemic World (T-AP RRR)
A monthly funding newsletter from PIVOT is sent to 3i investigators on the 2nd Monday of the month. If you have not been receiving the newsletter and would like to be added, please email Nicole.Frank@hsc.utah.edu.
| |
|
3i Investigator PublicationsCongratulations to the teams who published this week. If you have a publication that you would like included, please email us.
| |
|
Memory consolidation is thought to occur through protein synthesis-dependent synaptic plasticity mechanisms such as long-term potentiation (LTP). Dynamic changes in gene expression and epigenetic modifications underlie the maintenance of LTP. Similar mechanisms may mediate the storage of memory. Key plasticity genes, such as the immediate early gene Arc, are induced by learning and by LTP induction. Mice that lack Arc have severe deficits in memory consolidation and Arc has been implicated in...
A substantial fraction of the human genome is difficult to interrogate with short-read DNA sequencing technologies due to paralogy, complex haplotype structures, or tandem repeats. Long-read sequencing technologies, such as Oxford Nanopore's MinION, enable direct measurement of complex loci without introducing many of the biases inherent to short-read methods, though they suffer from relatively lower throughput. This limitation has motivated recent efforts to develop amplification-free...
The regulation of mean arterial pressure (MAP) during exercise has important physiological and clinical implications. Kinetics analysis on numerous physiological variables following the transition from unloaded-to-loaded exercise has revealed important information regarding their control. Surprisingly, the dynamic response of MAP during this transition remains to be quantified. Therefore, ten healthy participants (5/5 M/F, 24±3 years) completed repeated transitions from unloaded to moderate- and...
Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) from HLA-identical related donors using cyclosporine (CSP) and mycophenolate mofetil (MMF) for postgrafting immunosuppression is effective therapy for hematologic cancers. However, graft-versus-host-disease (GVHD) remains a major cause of morbidity and mortality. Pilot data suggested lower acute GVHD incidence with tacrolimus/MMF compared to historical experience using CSP/MMF after nonmyeloablative HCT. In a phase II...
CONCLUSIONS: Organizations that offer primary care for persons experiencing homelessness can improve the primary care experience by tailoring the design and delivery of services.
CONCLUSIONS: In an international, consortium-based study, animal protein was consistently associated with increased circulating TMAO, whereas TMAO associations with fish, shellfish, eggs, and red meat varied among populations. The adverse associations of TMAO with certain cardiometabolic biomarkers, independent of renal function, warrant further investigation.
Background Few adults at high risk for atherosclerotic cardiovascular disease events use a PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitor). Methods and Results Using data from the US Veterans Health Administration, we identified veterans who initiated a PCSK9i between January 2018 and December 2019, matched 1:4 to veterans who did not initiate this medication over this time period (case-cohort study). Two cohorts of veterans were analyzed: (1) atherosclerotic cardiovascular...
CONCLUSIONS: Clinically significant differences in obstetric interventions and outcomes do not appear to exist based on temporal proximity to attending physician shift change. Future work should attempt to directly study unit culture and provider fatigue in order to further investigate opportunities to improve obstetric quality of care, and additional studies are needed to corroborate these findings in community settings.
Changes in the gut microbiome have already been associated with postoperative complications in major abdominal surgery. However, it is still unclear whether these changes are transient or a long-lasting effect. Therefore, the aim of this prospective clinical pilot study was to examine long-term changes in the gut microbiota and to correlate these changes with the clinical course of the patient. Methods: In total, stool samples of 62 newly diagnosed colorectal cancer patients undergoing primary...
Articular cartilage defects represent an inciting factor for future osteoarthritis (OA) and degenerative joint disease progression. Despite multiple clinically available therapies that succeed in providing short term pain reduction and restoration of limited mobility, current treatments do not reliably regenerate native hyaline cartilage or halt cartilage degeneration at these defect sites. Novel therapeutics aimed at addressing limitations of current clinical cartilage regeneration therapies...
Incomplete relapse recovery contributes to disability accrual and earlier onset of secondary progressive multiple sclerosis. We sought to investigate the effect of age on relapse recovery. We identified patients with multiple sclerosis from two longitudinal prospective studies, with an Expanded Disability Status Scale (EDSS) score within 30 days after onset of an attack, and follow-up EDSS 6 months after attack. Adult patients with multiple sclerosis (n = 632) were identified from the Comprehensive Longitudinal Investigations in Multiple Sclerosis at Brigham study (CLIMB), and paediatric patients (n = 132) from the US Network of Paediatric Multiple Sclerosis Centers (NPMSC) registry. Change in EDSS was defined as the difference in EDSS between attack and follow-up. Change in EDSS at follow-up compared to baseline was significantly lower in children compared to adults (P = 0.001), as were several functional system scores. Stratification by decade at onset for change in EDSS versus age found for every 10 years of age, EDSS recovery is reduced by 0.15 points (P < 0.0001). A larger proportion of children versus adults demonstrated improvement in EDSS following an attack (P = 0.006). For every 10 years of age, odds of EDSS not improving increase by 1.33 times (P < 0.0001). Younger age is associated with improved recovery from relapses. Age-related mechanisms may provide novel therapeutic targets for disability accrual in multiple sclerosis.
| |
|
|
|
|
